TEL AVIV, Israel, Aug. 17 /PRNewswire/ -- Nucleix, Ltd., an emerging life science company specializing in forensic DNA analysis, announced today that Meirav Chovav, a veteran biotechnology industry analyst and consultant, is joining the company as Vice President of Strategic Affairs. Ms. Chovav has also been elected to the company's Board of Directors.
With more than 20 years of industry and research experience, focused on in-depth coverage and analysis of the biotechnology sector, Ms. Chovav brings astute strategic and business development perspective to Nucleix. In this newly-created position, Ms. Chovav will be responsible for overseeing corporate strategy, reporting to Elon Ganor, MD, Nucleix's Chairman and Chief Executive Officer.
"We are very pleased to add Meirav to the company's management team and to the board," said Dr. Ganor. "Meirav's rich industry knowledge and strategic vision will be extraordinarily valuable as we seek to integrate Nucleix's revolutionary insights and technology in the forensic DNA testing process."
"I am very excited to join the Nucleix team, and have this unique opportunity to resume my work in the industry as an active participant in an emerging company," said Ms. Chovav. "Nucleix's focus, breakthrough research and technology and remarkable accomplishments are very impressive. In many ways, Nucleix is reminiscent of some of the outstanding opportunities that I have had the good fortune to be associated with during my Wall Street career."
Ms. Chovav holds an MBA from Rensselaer Polytechnic Institute and an MS in molecular biology from the University of Rochester. A well-respected biotechnology research analyst, Ms. Chovav is renowned for her original coverage of large cap biotechnology companies such as AMGEN, Genentech and Biogen, in addition to many other leading life sciences companies. From 1993-2004, Ms. Chovav led co
|SOURCE Nucleix, Ltd.|
Copyright©2009 PR Newswire.
All rights reserved